Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
This product is based on Osmotic Controlled Release Oral Delivery System technology
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
The joint venture will help both the parties to further develop the high-margin service business
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India
The company is in the process of appointing a new CFO.
40,000 visitors and representatives of more than 80 countries set to visit the show
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
Subscribe To Our Newsletter & Stay Updated
